Pharmacotherapy to sustain the fully remitted state

Journal of Psychiatry and Neuroscience

Volumn 27, Issue 4, 2002, Pages 269-280

  Kennedy, Sidney ^a   McIntyre, Roger ^a   Fallu, Angelo ^a   Lam, Raymond ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Antidepressive agents; Depressive disorder; Dose response relationship, drug; Drug therapy; Lithium carbonate; Recurrence; Remission induction; Treatment outcome

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; IMIPRAMINE; LITHIUM CARBONATE; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DOSE RESPONSE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HAMILTON SCALE; HUMAN; INCIDENCE; MAINTENANCE THERAPY; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; RECURRENT DISEASE; RELAPSE; REMISSION; RISK FACTOR; SCORING SYSTEM; SYMPTOM;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; RECURRENCE; REMISSION INDUCTION; TIME FACTORS;

EID: 0036655375     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. The clinical course of unipolar major depressive disorders
2. How recurrent and predictable is depressive illness
3. Time to recovery, chronicity and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects
4. Future imperfect: The long-term outcome of depression
5. Cost utility of maintenance treatment for recurrent depression
6. The course of affective disorders
7. Recovery from major depression: A 10-year prospective follow-up across multiple episodes
8. Continuation drug therapy for major depressive episodes: How long should it be maintained?
9. Recognition and management of depression in general practice: A consensus statement
10. Guidelines for treating depressive illness with antidepressants
11. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence
12. Relapse and recurrence of depression: A practical approach for prevention
13. Management of recurrent depression
14. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome
15. Timing of onset of antidepressant response with fluoxetine treatment
16. Antidepressants in clinical practice: Limitations of assessment methods and drug response
17. Early onset of antidepressant action of venlafaxine: Pattern analysis in intent-to-treat patients
18. Remission and residual symptomatology in major depression
19. Remission onset and relapse in depression. An 18-month prospective study of course for 100 first-admission patients
20. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: A survey of clinicians
21. Selective serotonin reuptake inhibitor treatment in the UK: Risk of relapse or recurrence of depression
22. Cognitive behavioral treatment of residual symptoms primary major depressive disorder
23. Evolution of remission as the new standard in the treatment of depression
24. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability
25. Amitriptyline v. the rest: Still the leading antidepressant after 40 years of randomised controlled trials
26. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients
27. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly
28. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: A double-blind randomized trial
29. SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression
30. Responders to antidepressant drug treatment: A study comparing nefazodone, imipramine, and placebo in patients with major depression
31. A comparison of nefazodone, the cognitive behavioural-analysis system of psychotherapy and their combination therapy for the treatment of chronic depression
32. Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults
33. Moclobemide: A reversible MAO-A inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicentre study
34. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression
35. Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe depressive disorder
36. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression
37. Randomized, double-blind comparison of veniafaxine and sertraline in outpatients with major depressive disorder
38. Venlafaxine and paroxetine in treatment resistant depression
39. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia
40. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
41. Efficacy of venlafaxine in depressive illness in general practice
42. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
43. Are two antidepressant mechanisms better than one?
44. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis
45. Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse
46. Residual symptoms after partial remission: An important outcome in depression
47. Relapse of depression in primary care: Rate and clinical predictors
48. Imipramine in depression
49. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression
50. Treatment of major depression
51. Lifetime and 12-month prevalence of DSM-III psychiatric disorders in the United States
52. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment
53. Two-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate
54. Loss of antidepressant efficacy during maintenance therapy: Possible mechanisms and treatments
55. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression
56. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
57. Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial
58. Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate
59. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression
60. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: A placebo-controlled 6-month study
61. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder
62. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression
63. Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression
64. Venlafaxine prevents recurrence of depression
65. Efficacy of mirtazapine for prevention of depressive relapse: A placebo-controlled double-blind trial of recently remitted high-risk patients
66. Long-term prophylactic pharmacologic treatment of bipolar illness
67. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression
68. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders
69. Continuation ECT: Relapse prevention in affective disorders
70. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: A comparison with imipramine and placebo in medium-term continuation therapy
71. Efficacy of continuation ECT and antidepressant drugs compared to longterm antidepressants alone in depressed patients